实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 883-886.doi: 10.3969/j.issn.1672-5069.2023.06.029

• 肝癌 • 上一篇    下一篇

肝细胞癌患者癌组织CK7和Glypican-3表达及其临床意义探讨*

杨婉, 丁莉, 罗珂, 刘美   

  1. 448000 湖北省荆门市中心医院病理科(杨婉,丁莉,罗珂);三峡大学第一临床医学院宜昌市中心人民医院检验科(刘美)
  • 收稿日期:2023-05-12 出版日期:2023-11-10 发布日期:2023-11-20
  • 通讯作者: 丁莉,E-mail:dl789521@126.com
  • 作者简介:杨婉,女,41岁,大学本科,主管技师。E-mail:jmzxyyyw@163.com
  • 基金资助:
    * 湖北省自然科学基金资助项目(编号:ZRMS2017000916)

Clinical implications of cancerous tissue CK7 and glypican-3 expression in patients with hepatocellular carcinoma

Yang Wan, Ding Li, Luo Ke, et al   

  1. Department of Pathology, Central Hospital, Jingmen 448000,Hubei Province,China
  • Received:2023-05-12 Online:2023-11-10 Published:2023-11-20

摘要: 目的 探讨肝细胞癌(HCC)患者癌组织细胞角蛋白7(CK7)和磷脂酞肌醇蛋白聚糖-3(GPC3)表达及其临床意义。方法 2018年4月~2022年1月我院诊治的219例HCC患者,行开腹肝叶切除术治疗,术后随访1年。采用免疫组化法检测HCC癌组织和癌旁组织CK7和GPC3表达,采用Kaplain-Maier法描绘生存曲线,采用Log Rank检验比较生存率的差异。结果 癌组织CK7和GPC3阳性表达率分别为33.3%和63.5%,显著高于癌旁组织的15.5%和21.9%(P<0.05);肿瘤细胞低分化、BCLC C期、有血管侵犯、癌栓和存在肝外转移患者癌组织CK7阳性表达率分别为57.1%、47.2%、50.0%、51.9%和59.5%,显著高于对应组的16.4%、20.4%、24.1%、22.5%和28.0%(P<0.05),GPC3阳性表达率分别为79.1%、76.4%、82.1%、81.5%和86.5%,均显著高于对应组的52.3%、51.3%、53.2%、52.9%和58.8%(P<0.05);在随访1年末,本组HCC患者生存率为75.8%;癌组织CK7阴性患者1 a生存率为80.1%,显著高于CK7阳性患者的67.1%(P<0.05),癌组织GPC3阴性患者1 a生存率为85.0%,显著高于GPC3阳性患者的70.5%(P<0.05)。结论 HCC癌组织CK7和GPC3呈现高表达,可能与肿瘤恶性程度和侵袭力相关,预示患者预后不良,值得深入研究。

关键词: 肝细胞癌, 细胞角蛋白7, 磷脂酞肌醇蛋白聚糖-3, 表达, 预后

Abstract: Objective The aim of this study was to investigate the clinical implications of cancerous tissue cytokeratin 7 (CK7) and glypican-3 (GPC3) expression in patients with hepatocellular carcinoma (HCC). Methods A total of 219 patients with HCC were enrolled in our hospital between April 2018 and January 2022, and all underwent radical hepatectomy. The patients were followed-up for one year. The expressions of CK7 and GPC3 in cancerous and its adjacent liver tissues were detected by immunohistochemistry. The survival curves were drawn by Kaplain-maier method and the differences of survival rate between patients with CK7 and GPC3 positive and negative were compared by Log Rank test. Results The positive rates of cancerous tissue CK7 and GPC3 expression were 33.3% and 63.5%, significantly higher than 15.5% and 21.9%(P<0.05) in the adjacent liver tissues; the positive rates of cancerous tissue CK7 expression in low differentiated tumors, BCLC stage C, tumors with vascular invasion, portal cancerous embolus and extrahepatic metastasis were 57.1%, 47.2%, 50.0%, 51.9% and 59.5%, all significantly higher than 16.4%, 20.4%, 24.1%, 22.5% and 28.0%(P<0.05), and the positive rates of cancerous tissue GPC3 expression were 79.1%, 76.4%, 82.1%, 81.5% and 86.5%, all much higher than 52.3%, 51.3%, 53.2%, 52.9% and 58.8%(P<0.05) in their surrounding liver tissues; at the end of one-year follow-up, the survival rate in our series was 75.8%; the one-year survival rate in patients with cancerous tissue CK7 negative was 80.1%, much higher than 67.1%(P<0.05)in those with CK7 positive, and the one-year survival rate of patients with cancerous GPC3 negative was 85.0%, much higher than 70.5%(P<0.05) in those with GPC3 positive. Conclusion The expressions of CK7 and GPC3 in cancerous tissues are up-regulated in patients with HCC, which might be correlated to tumor malignance and invasiveness.

Key words: Hepatoma, Cytokeratin 7, Glypican-3, Expression, Prognosis